Onco-Hu Mouse Models for Cancer Immunotherapy Research Explained

April 13, 2020

Onco-Hu® models are a robust immuno-oncology platform for efficacy testing of novel immunotherapies targeting T cells and myeloid cells. The platform is based on NSG™ and NSG™-SGM3 transgenic mice, dually engrafted with human CD34+ hematopoietic stem cells (HSCs) and clinically relevant PDX Live™ low passage tumors. Watch this video to learn more about Onco-Hu® mouse models.

Onco-Hu Mouse Models for Cancer Immunotherapy Research Explained

Cancer immunotherapy: getting a little help from ourselves

Comparing Immune-Humanized Mouse Platforms for Preclinical Applications

Comparing Immunodeficient Models for Cancer, Immunity, and Transplant Research

New Immune-humanized Models Support More Diverse Human Immune Cell Lineages

The Promise of Cancer Genomics

Exploring Cancer Research: Tools and Technologies

Leveraging Gene Therapy to Achieve Long-Term Continuous or Controllable Expression of Biotherapeutics

JAX Clinical Knowledgebase - Identify Resistance Variants in Preclinical Drug Testing

Making a Case for Preclinical Data - The JAX Clinical Knowledgebase

A Novel In Vivo Model to Simultaneously Assess Efficacy and Toxicity of Chimeric Antigen Receptor T-Cell Immunotherapy

Exploring Cancer: Biology and Inheritance

Immune-Humanized PDX Model-Estrogen-Independent, Hormone Receptor-Positive Metastatic Breast Cancer

Predictive Pre Clinical Oncology Studies Using Patient-Derived Xenograft Platforms

How To Make Your New NSG Variant in a Fraction of the Time

Achieving Relevant Preclinical Characterization of CAR T Cell Therapies

Designing Your In Vivo Studies

JAX Tech Talk Episode 48: Developing Immunotherapies with Hu-NSG-MHC I/II DKO Mice (Jan. 11, 2022)

JAX Tech Talk Episode 47: Let’s Talk Navigating the JAX Clinical Knowledgebase (Dec. 14, 2021)

Introduction to In Vivo Platforms for Cancer Immunotherapy

Human KIT+ Myeloid Cells Facilitate Visceral Metastasis By Melanoma